The HYDILE Trial: Efficacy and Tolerance of a Quadruple Combination of Reverse Transcriptase Inhibitors Versus the Same Regimen Plus Hydroxyurea or Hydroxyurea and Interleukin-2 in HIV-Infected Patients Failing Protease Inhibitor-Based Combinations

REFERENCES

• Panda FJ, Delanay KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Devereux H, Kinloch-de-Loes S, et al. Immuno-logical, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 2000;14:1545–1552.
   PubMed Web of Science ®Google Scholar
• O'Brien WA. Resistance against reverse transcriptase in-hibitors. Clin Infect Dis. 2000;30\(suppl 2):S185–192.
   PubMed Web of Science ®Google Scholar
• Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and geno-typic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 2000;16:1203–1210.
   Web of Science ®Google Scholar
• Rutschmann OT, Vernazza PL, Bucher HC, et al. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. AIDS. 2000;14:2145–2151.
   PubMed Web of Science ®Google Scholar
• Lori F. Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS. 1999;13:1433–1442.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT. The potential role of interleukin-2 in HIV. AIDS. 2001;15\(suppl 2):522–27.
   Google Scholar
• Schockmel G, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retroyirol. 1997;17:179–183.
   Google Scholar
• Yanovski JA, Miller KD, Kino T, et al. Endocrine and meta-bolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated li-podystrophy. J Clin Endocrinol Metab. 1999;84:1925–1931.
   PubMed Web of Science ®Google Scholar
• The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommenda-tions for the European setting. AIDS. 200115: 309–320.
   Google Scholar
• Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS. 2001;15:117–119.
   PubMed Web of Science ®Google Scholar
• Khanna N, Klimkait T, Schiffer V, et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase in-hibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study. AIDS. 2000;14:791–799.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Rizzo E, Calza L, Chiodo F. The use of efavirenz as a part of late rescue antiretroviral treatment. HIV Clin Trials. 2001;2(5):413–420.
   PubMedGoogle Scholar
• Montaner JSG, Mo T, Raboud JM, et al. Human immuno-deficiency virus-infected persons with mutations confer-ring resistance to zidovudine show reduced virologic re-sponse to hydroxyurea and stavudine-lamivudine. J Infect Dis. 2000;181:729–732.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Poggi C, Hittinger G, Chadapaud S. Pheno-typic and genotypic resistance to nucleoside reverse tran-scriptase inhibitors in HIV-1 clinical isolates. HIV Med. 2001;2(4):231–235.
   PubMedGoogle Scholar
• Shulman NS, Machekano RA, Shafer RW, et al. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr. 2001;27:377–380.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Montaner JSG, Wegener SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in un-treated individuals: biological relevant values for resistance testing. AIDS. 200115:1671–1677.
   Google Scholar
• Henry K, Wallace RJ, Bellman PC, et al. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET study. J Infect Dis. 2001;183:571–578.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Wilkins E, Leen C, Cheesbrough A, Reynolds B, Gazzard BG. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-infected persons with previous nucleo-side analogue and protease inhibitor use. AIDS. 2000;14:1453–1454.
   PubMed Web of Science ®Google Scholar
• Tenorio AR, Irlandal E, Narkiewicz E, Smith KY, Kessler HA, Sha BE. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy. AIDS. 2000;14:1470–1471.
   PubMed Web of Science ®Google Scholar
• Lanier ER, Kubota M, Yau L, Hessenthaler S, Hernandez J. Diverse effects of NRTI-associated mutations on resis-tance to abacavir, stavudine and zidovudine in the ZORRO trial. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL. Abstract 1761.
   Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochon-drial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet. 1999;354:1112–1115.
   PubMed Web of Science ®Google Scholar
• Hengge UR, Borchard C, Esser S, Schroder M, Mirmohammadsadegh A, Goss M. Lymphocytes prolifer-ate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy. AIDS. 2002;16:151–160.
   PubMed Web of Science ®Google Scholar
• Reisler K. High hepatotoxicity rate seen among HAART patients. Aids Alert. 200116: 118–119.
   Google Scholar
• Foli A, Benvenuto F, Piccini G, et al. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS. 2001;15:1687–1694.
   PubMed Web of Science ®Google Scholar
• Melial SA, John M, Moore CB, et al. Contribution of nucleo-side analogue reverse transcriptase inhibitors to subcuta-neous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316.
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 pro-tease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266–1273.
   PubMed Web of Science ®Google Scholar